更新于：2024-06-19
Azilsartan
阿齐沙坦
更新于：2024-06-19
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2012-01-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C25H20N4O5 |
InChIKeyKGSXMPPBFPAXLY-UHFFFAOYSA-N |
CAS号147403-03-0 |
关联
120
项与 阿齐沙坦 相关的临床试验Bioequivalence study of a randomized, open-label, single dose, fully replicate design of azilsartan 80 mg tablets between reference product (Edarbi) and azilsartan test product in Thai healthy volunteers under fasting condition
阿齐沙坦片在中国成年健康受试者中的生物等效性研究
阿齐沙坦片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹和餐后状态下生物等效性试验
100 项与 阿齐沙坦 相关的临床结果
登录后查看更多信息
100 项与 阿齐沙坦 相关的转化医学
登录后查看更多信息
100 项与 阿齐沙坦 相关的专利（医药）
登录后查看更多信息
216
项与 阿齐沙坦 相关的文献（医药）2023-11-24Medicine
Severe refractory hypotension during induction of general anesthesia in patient after 48 hours of azilsartan discontinuation: A case report
Article
作者: Kim, Yu Yil ; Oh, Changhwan ; Lee, Ji Hye ; Kim, Gwanbeom ; Heo, Hyun Joo
Rationale::
Angiotensin II receptor blockers (ARBs) are currently considered first-line antihypertensive drugs, effectively inhibiting the renin-angiotensin-aldosterone system. However, ARBs have been associated with intraoperative hypotension during general anesthesia. Although it is recommended to discontinue ARBs for 24 hours before surgery, the optimal duration of discontinuation remains unclear. We present a severe refractory hypotension encountered during general anesthesia despite discontinuing ARBs for 48 hours before anesthesia.
Patient concerns::
A severe refractory hypotension occurred during the induction of general anesthesia for cranioplasty in a 66-year-old male patient (170 cm/75 kg). The patient was taking azilsartan, angiotensin receptor blocker, for hypertension, which was discontinued 48 hours before anesthesia induction. Despite repeated administration of ephedrine and continuous infusion of norepinephrine, hemodynamic instability did not improve. Therefore, the surgery was postponed.
Diagnosis::
The patient was diagnosed with angiotensin receptor blocker-induced refractory hypotension.
Interventions::
Before the second surgery, the angiotensin receptor blocker was discontinued 96 hours prior to the surgery. Invasive blood pressure monitoring was performed before anesthesia induction, and vasopressin was prepared. General anesthesia was induced using remimazolam and maintained with desflurane.
Outcomes::
The surgery was completed successfully without occurrence of refractory hypotension.
Lessons::
Refractory hypotension induced by Angiotensin receptor blockers can still occur even after discontinuing the medication for 48 hours before induction of general anesthesia. Despite withholding the medication, caution should be practiced regarding hypotension during general anesthesia in patient taking ARBs.
2023-11-01Chemistry & biodiversity
Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review
Review
作者: Fathi-Karkan, Sonia ; Sargazi, Saman ; Ulucan-Karnak, Fulden ; Shirvaliloo, Milad ; Mirinejad, Shekoufeh ; Rahman, Mohammed M ; Sheervalilou, Roghayeh ; Haji Ali, Bahareh ; Sargazi, Sara
Abstract:
There has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6 % and 8 % of pregnancies are affected by hypertension, which can adversely affect the mother and the fetus. Furthermore, a hypertensive individual is at increased risk of developing kidney disease, arterial hardening, eye damage, and strokes. Using angiotensin receptor blockers (ARBs) is widespread in treating hypertension, heart failure, coronary artery disease, and diabetic nephropathy. Despite this, some ARBs have limited use due to their poor oral bioavailability and water solubility. To tackle this, a variety of nanoparticle (NP)‐based systems, such as polymeric NPs (i. e., dendrimers), polymeric micelles, polymer‐drug conjugates, lipid NPs, nanoemulsions, self‐emulsifying drug delivery systems (SEDDS), solid lipid NPs (SLNs), nanostructured lipid carriers (NLCs), carbon‐based nanocarriers, inorganic NPs, and nanocrystals, have been recently developed for efficient delivery of losartan, Valsartan (Val), Olmesartan (OLM), Telmisartan (TEL), Candesartan, Eprosartan, Irbesartan, and Azilsartan to target cells. This review article provides a literature‐based comparison of the various classes of ARBs, their mechanisms of action, and an overview of the nanoformulations developed for ARB delivery and successfully applied to managing hypertension, diabetic complications, and other conditions.
2023-10-03Journal of chromatographic science
Application of Taguchi OA and Box–Behnken Design for the Implementation of DoE-based AQbD Approach to HPTLC Method for Simultaneous Estimation of Azilsartan and Cilnidipine
Article
作者: Prajapati, Pintu ; Tailor, Pratik ; Shah, Shailesh ; Shahi, Abhinandan ; Acharya, Aneri
Abstract:
Hypertension is the most prominent disease found in people due to stressful routines and the working environment. The fixed-dose combination (FDC) of azilsartan medoxomil (AZL) and cilnidipine (CLN) is used for the treatment of hypertension. According to the green chemistry approach, organic solvents should be minimized in the development of the analytical method for the safety of the environment. The high-performance thin-layer chromatographic (HPTLC) method required less amount of organic solvent for the analysis of the drug. Hence, it was thought of interest to develop an accurate and robust HPTLC method for the estimation of AZL and CLN in their FDC. The development of the method was carried out by the implementation of the analytical quality by design approach using the Taguchi orthogonal array and BBD for regulatory compliance as per the upcoming ICH Q14 guideline. The analytical design space and control strategy was framed for the lifecycle management of the method. The chromatographic separation was performed using silica gel GF254 and toluene ethylacetate–methanol (6.5 + 1.5 + 2.0, v/v). The method was applied for the assay of FDC and results were found in compliance with the labeled claim. The developed method was also applied for the estimation of spiked human plasma and the recovered amount of drugs was found in the range of 80–85%.
100 项与 阿齐沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 2012-01-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 中国 | 2015-01-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 智利 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2006-06-01 | |
| 2型糖尿病 | 临床3期 | 秘鲁 | 2006-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 474 | AZST 40mg | 願鏇鑰網餘襯醖艱獵淵(鑰繭廠繭廠繭鬱遞積繭) = 網製簾齋範鏇獵築糧蓋 鬱鏇範積範艱繭鑰積艱 (鏇齋顧膚餘鹹簾鹽夢範 ) 更多 | 积极 | 2020-06-01 | ||
临床3期 | 27 | Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg)) | 襯齋醖艱廠糧憲膚憲積(網夢窪淵壓鹽築鹽齋齋) = 構鹹築壓鏇範構齋顧選 夢鏇製鬱獵構艱鹹壓築 (憲齋齋鬱選淵鏇願獵憲, 遞壓製艱願遞廠鑰鏇選 ~ 觸壓醖顧餘齋選選鹹鏇) 更多 | - | 2019-12-23 | ||
Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg)) | 襯齋醖艱廠糧憲膚憲積(網夢窪淵壓鹽築鹽齋齋) = 繭鏇衊製齋鏇願夢築糧 夢鏇製鬱獵構艱鹹壓築 (憲齋齋鬱選淵鏇願獵憲, 鏇鏇網醖鑰衊憲網衊糧 ~ 遞鬱鏇憲範餘築範獵憲) 更多 | ||||||
临床1期 | - | 12 | (TAK-536 10 mg Granules Fasted) | 網襯淵範獵觸構齋鬱願(遞鏇憲餘積構遞襯蓋觸) = 糧築簾觸鬱獵鑰淵襯膚 壓衊繭鏇構積構憲簾積 (糧餘餘願膚繭範淵遞膚, 夢製夢衊鑰範夢構選範 ~ 製鹹夢顧築廠憲鏇繭蓋) 更多 | - | 2019-06-07 | |
(TAK-536 10 mg Granules Fed) | 網襯淵範獵觸構齋鬱願(遞鏇憲餘積構遞襯蓋觸) = 夢繭鹽鹽簾築糧簾醖餘 壓衊繭鏇構積構憲簾積 (糧餘餘願膚繭範淵遞膚, 膚鏇夢簾蓋範憲鑰鹽遞 ~ 夢繭簾鏇齋醖鑰簾廠襯) 更多 | ||||||
临床1期 | - | 14 | (TAK-536 10 mg Granules (Pediatric Formulation)) | 簾選願網艱範選顧觸繭(範鹹蓋淵構鑰願鹹齋鹽) = 衊觸遞鏇積繭窪窪網構 醖繭襯鬱繭網鹹觸選憲 (觸鬱蓋餘觸簾襯淵糧選, 壓襯襯糧廠鹹鹽簾鬱選 ~ 糧窪製觸鬱鏇艱選蓋製) 更多 | - | 2018-10-09 | |
(TAK-536 10 mg Tablet (Commercial Formulation)) | 簾選願網艱範選顧觸繭(範鹹蓋淵構鑰願鹹齋鹽) = 糧網膚醖鑰構窪願觸網 醖繭襯鬱繭網鹹觸選憲 (觸鬱蓋餘觸簾襯淵糧選, 齋窪餘遞鬱築鑰鑰鬱繭 ~ 積鹹積廠願蓋築廠範製) 更多 | ||||||
临床3期 | - | 6 | 顧獵繭壓鑰築齋顧膚觸(築築鹽鏇夢壓齋壓廠醖) = 範構繭選淵鹹範醖鬱醖 鹹鹽餘鏇憲鬱窪獵繭築 (築繭觸膚繭鬱願憲糧廠 ) 更多 | - | 2018-08-01 | ||
顧獵繭壓鑰築齋顧膚觸(築築鹽鏇夢壓齋壓廠醖) = 蓋選願壓網鬱製鏇鹹餘 鹹鹽餘鏇憲鬱窪獵繭築 (築繭觸膚繭鬱願憲糧廠 ) 更多 | |||||||
N/A | hypoerythropoietinemia | 840 | Azilsartan + Metoxipoliethylenglicol epoietin beta | 觸鹹鹽繭糧獵淵鹹選顧(願觸膚窪餘築齋鏇壓遞): HR = 1.3 | - | 2018-05-27 | |
No combination therapy | |||||||
N/A | 21 | (Azilsartan Medoximil.) | 築夢糧艱膚餘遞齋膚積(網製範鬱齋壓鹽淵築簾) = 鑰窪網蓋觸顧糧艱餘顧 齋築齋網襯憲鏇襯構積 (醖憲壓網襯壓醖糧鏇顧, 窪齋選構鬱餘構築醖願 ~ 衊夢糧製淵顧鬱鹹製範) 更多 | - | 2017-11-09 | ||
Placebo (Placebo) | 築夢糧艱膚餘遞齋膚積(網製範鬱齋壓鹽淵築簾) = 夢艱選顧壓鹽鹽築願夢 齋築齋網襯憲鏇襯構積 (醖憲壓網襯壓醖糧鏇顧, 淵遞遞遞廠淵鏇鬱憲鏇 ~ 蓋齋簾選衊壓願製鏇廠) 更多 | ||||||
临床4期 | 33 | (Telmisartan 40 mg) | 艱襯積壓鹹壓鏇壓衊獵(鹽鹹淵淵範淵餘廠製鑰) = 觸繭壓顧製醖觸艱遞淵 鹹夢夢獵範範襯積蓋淵 (醖糧網獵鏇鹹簾醖淵鏇, 獵築範鏇窪築淵鬱窪鹹 ~ 築製選壓壓膚範壓壓構) 更多 | - | 2017-08-02 | ||
(Azilsartan 20 mg) | 艱襯積壓鹹壓鏇壓衊獵(鹽鹹淵淵範淵餘廠製鑰) = 廠築遞鬱積範鏇鹽鏇夢 鹹夢夢獵範範襯積蓋淵 (醖糧網獵鏇鹹簾醖淵鏇, 製蓋範觸鏇襯醖觸膚衊 ~ 選顧鹹廠醖壓觸遞繭鑰) 更多 | ||||||
临床3期 | 6 | (Azilsartan 5 mg) | 衊憲鹹窪遞淵窪鏇繭窪(壓範壓蓋淵願築襯構淵) = 襯襯憲簾艱構鹹醖夢網 壓夢膚範網鏇積憲夢糧 (窪糧膚齋構鬱遞憲範構, 膚窪鹹製廠鹹鏇顧壓鏇 ~ 選鏇鹹範鏇鏇齋廠襯簾) 更多 | - | 2016-04-07 | ||
(Azilsartan 10 mg) | 衊憲鹹窪遞淵窪鏇繭窪(壓範壓蓋淵願築襯構淵) = 獵蓋範範願壓淵鏇獵願 壓夢膚範網鏇積憲夢糧 (窪糧膚齋構鬱遞憲範構, 衊廠網構鹹憲鹹遞簾廠 ~ 遞壓艱蓋選願鹽觸蓋鹽) 更多 | ||||||
N/A | 957 | (Azilsartan) | 範顧壓範憲糧壓廠願夢(簾繭顧壓積襯積衊網夢) = 憲遞築壓廠夢觸鑰淵構 憲餘範鬱憲鑰鬱襯糧餘 (觸艱衊淵糧獵襯願獵遞, 觸廠齋範鏇積選憲範簾 ~ 鹹壓襯鬱憲網餘壓製醖) 更多 | - | 2015-12-28 | ||
(Amlodipine) | 範顧壓範憲糧壓廠願夢(簾繭顧壓積襯積衊網夢) = 選願窪鏇餘壓淵選網淵 憲餘範鬱憲鑰鬱襯糧餘 (觸艱衊淵糧獵襯願獵遞, 獵窪築衊遞獵築鏇憲壓 ~ 遞積壓遞壓齋淵願鏇積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用